AN OPEN MULTICENTRIC STUDY EVALUATING 4-HYDROXYBUTYRIC ACID SODIUM SALT IN THE MEDIUM-TERM TREATMENT OF 179 ALCOHOL DEPENDENT SUBJECTS
|
|
- John Burke
- 6 years ago
- Views:
Transcription
1 Alcohol & Alcoholism Vol. 31, No. 4, pp , 1996 AN OPEN MULTICENTRIC STUDY EVALUATING 4-HYDROXYBUTYRIC ACID SODIUM SALT IN THE MEDIUM-TERM TREATMENT OF 179 ALCOHOL DEPENDENT SUBJECTS G. ADDOLORATO*. E. CASTELLI 1, G. F. STEFANINI 1, G. CASELLA 1, F. CAPUTO 1, L. MARSIGLI 1, M. BERNARDI 1, G. GASBARRINI and GHB STUDY GROUP 2 Internal Medicine 11 Chair, Catholic University 'Sacro Cuore', Rome, Italy, ''G. Fontana' Centre for the Study and Multidisciplinary Treatment for the Inadequate Use of Alcohol, University of Bologna, Italy and "Various participating centres (Received 8 August 1995; in revised form 16 November 1995; accepted 10 December 1995) Abstract We report the results of an 'open' multicentre study evaluating the use, tolerability and therapeutic efficacy of the sodium salt of 4-hydroxybutyric acid (GHB) for the medium-term treatment of withdrawal symptoms in 179 patients with alcohol dependence followed up as outpatients. The follow-up of patients was 6 and 12 months after drug discontinuation. Following a daily oral administration of 50mg/kg for approximately 6 months, no serious systemic or single-organ consequences leading to drug discontinuation were reported, and tolerability was fair in all patients. Eleven subjects (10.1%) showed craving for the drug and voluntarily increased their doses (6-7 times the recommended levels). GHB led to complete abstinence during drug administration in 78.0% of the patients. A significant reduction of compulsive desire ('craving') was observed in parallel, as deduced from evaluation of a specific questionnaire, the Alcohol Craving Scale. At follow-up examination, 43 of the treated subjects remained abstinent at 6 months, and 30 subjects were abstinent for 1 year after drug discontinuation. INTRODUCTION The principles of alcohol dependence therapy are essentially based on intervention through psychological support (Bien et al, 1993) and the use of drug therapy. The role of drug therapy, however, has not yet been well established (US Department of Health and Human Services, 1990). Psychological and behavioural support interventions include various rehabilitation programmes (for example the Minnesota system, psychoeducational interventions, systemic family and group therapies) (Alcoholics Anonymous, 1978; Emrick, 1987; Jacobson et al, 1989; O'Farrel, 1989; US Department of Health and Human Services, 1990; Hermos, 1992; Addolorato et al, 1993a; Bien et al., 1993). At present, pharmacotherapy comprises numerous non-specific drugs, such as vitamins, minerals, drugs acting on the central nervous system (CNS) (anxiolytics, antidepressants and the major tran- Author to whom correspondence should be addressed at: Istituto di Paiologia Medica I, Universita' degli Studi di Bologna, Bologna, Italy. quillizers), and also specific drugs. Besides interdiction/aversion drugs (disulfiram, metronidazole, apomorphine etc.), substances with a compulsive desire (craving) reduction activity (fluoxetine, methadoxine, S-adenosyl-methionine, naltrexone, acamprosate) have been employed (Fuller et al, 1986; Lhuintre et al, 1990; Lieber et al, 1990; Gorelick and Paredes, 1992; O'Malley et al, 1992; Inturri et al., 1993; Gasbarrini et al, 1994; Soyka, 1995). Among the latter group, gamma-hydroxybutyric acid (GHB) has been introduced recently into clinical practice (Gallimberti et al, 1989, 1992; Addolorato et al., 1993fc; Di Bello et al., 1995). GHB, a metabolite of GABA, formerly used as a hypnotic/anaesthetic agent (Laborit et al, 1960; Mamelak et al, 1986), has been found in large quantities in the hypothalamus and basal ganglia and has been assigned neurotransmitter and neuromodulatory functions (Mamelak et al, 1986; Vayer et al, 1987). GHB administration is effective in preventing the abstinence syndrome in both experimental animals and man (Gallimberti et al, 1989) and in inducing short-term abstinence (Gallimberti et al, 1992). Since the majority of Medical Council on Alcoholism
2 342 G. ADDOLORATO et al. treatment failures occur within the first 6 months and studies on the medium-term effect of GHB in alcoholism treatment are lacking and, after having conducted a pilot study on 15 alcohol-dependent patients with promising results (Addolorato et al., 1993/?), we performed a multicentre study, firstly to evaluate the usefulness, tolerability and safety of GHB, and, secondly, to obtain an indication of GHB activity in prolonged outpatient weaning, using the parameters of abstinence and craving as measures of outcome. PATIENTS AND METHODS Nineteen centres from various Italian regions participated in the study. Alcohol-dependent patients were admitted to the study on the basis of DSM-III-R criteria (American Psychiatric Association, 1987). Eligible patients gave their informed consent. Pregnancy, severe kidney, heart or lung disease, decompensated liver cirrhosis, psychopathology under treatment with psychoactive drugs and epilepsy or epileptiform convulsions constituted exclusion criteria. On the basis of such criteria, 179 alcoholdependent subjects were enrolled and administered GHB. Of these, 131 subjects were males and 48 were females, between the ages of 18 and 73 (mean age 46), under outpatient treatment at the above centres. According to the DSM-IH-R criteria, of the 179 patients enrolled in the study, 59 (32.9%) had an alcohol dependence of mild severity, 55 (30.7%) had a moderate alcohol dependence and 65 (36.3%) had a severe alcohol dependence. The drug and its administration were entrusted to a designated family member; the drug was orally administered, at a dose of 50mg/kg three times/day for 24 weeks. All the patients were strongly advised against the use of drugs that can potentially influence the desire for alcohol consumption. Each subject was checked as an outpatient every 3 weeks for the 24-week duration; at each visit, routine psychological support counselling was provided and the patient was requested to complete the Alcohol Craving Scale (ACS). The questionnaire contained 14 items, each of which required a yes or no answer, corresponding to 1 or 0 points, respectively; thus, the maximum craving score was 14 (Gallimberti et al., 1992; Di Bello et GHB 6 12 Duration (months) Fig. 1. Abstinent patients throughout the period of GHB treatment and follow-up. al, 1995). Abstinence was evaluated on the basis of the patients' self-evaluation and on that by the family member, and laboratory tests, including blood alcohol concentration, gamma GT (GGT), mean cell volume (MCV), aspartate aminotransferase (AST), alanine aminotransferase (ALT), determination of alcohol in saliva by the QED saliva alcohol test (by Enzymatics Inc., Horsham, UK). Laboratory tests were repeated at 3 months and at the end of the study. The follow-up of the patients was at 6 months and 12 months after drug discontinuation. Statistical analysis was carried out by means of the Mann-Whitney (/-test for within-group comparison, and by the Wilcoxon test for comparisons between the different groups as regards ACS; Student's paired /-test was used to compare the results of laboratory tests before and after the study, and to compare the data between the different subgroups of patients. RESULTS Of the 179 patients enrolled in the study, 70 subjects (of whom 17 were females) dropped out (39.1%), whereas 109 subjects (31 of whom were females) continued drug therapy with GHB (60.9%). Of the 109 subjects, 84 (25 females and 59 18
3 GHB TREATMENT OF ALCOHOLISM 343 Table 1. The alcohol craving score of patients treated with gamma-hydroxybutyrate Patients n Craving score Start End * Significance (P) ** * Whole group ± ± 2.84 < Group A Group B ± ± ± ± 2.95 < n.s. <0.01 Group C Group D ± ± ± ± 1.66 <0.05 Group A: subjects abstinent throughout the period of treatment; Group B: subjects not abstinent throughout the period of treatment; Group C: subjects abstinent 1 year after drug discontinuation; Group D: subjects not abstinent 1 year after drug discontinuation. P between the mean values before and after the study within the sub-groups; * P between the mean values from the different groups at the start of treatment; *** P between the mean values from the different groups at the end of the study. n.s. males) became and remained abstinent throughout the experiment (78.0%) (Fig. 1), whereas 25 subjects (6 females and 19 males) relapsed; the majority of these (19 subjects) voluntarily discontinued the drug, in part complaining of a lack of reduced craving (14 subjects) or fear of sideeffects due to concomitant intake of alcohol and drugs (9 subjects). In the following 1-year period of observation, of the 84 subjects who maintained abstinence until termination of the treatment, 43 (51.2%) remained abstinent at 6 months of drug suspension (Fig. 1), whereas in 41 (48.8%) treatment failed (26 withdrew and 15 relapsed); at 1 year among abstinent patients this led to 35.7% (30 subjects) complete abstinence (Fig. 1). Some sporadic benzodiazepine intake was recorded both during the treatment time and the follow-up, without any significant difference between abstinent patients and relapsed ones. No serious systemic or single-organ side-effects leading to drug cessation were reported. Tolerability was fair in all patients; ~36% of the subjects reported vertigo, which resolved after about 3 weeks of treatment; another 28% reported increased sleepiness and tiredness, which resolved after 2-3 weeks of drug intake and did not recur. Eleven subjects showed craving for the drug (10.1%) and voluntarily increased their doses (6-7 times the recommended level) to obtain anxiolytic and hypnotic effects. Seven of these showed ACS mean score higher than 8.5; the DSM-III-R scores showed scattered values. Comparing laboratory investigations before and immediately after GHB administration in abstinent patients versus the relapsed ones, we observed a significant difference in final values of GGT (from mean value of 161 U/l to 55 U/l, for abstinent patients, P< 0.001, and from a mean value of 1194 U/l to 129 U/l, for relapsed patients). The reduction in AST (from mean starting value of 51 U/l to a final value of 35 U/l, for abstinent patients, P< 0.001, and from 58 U/l to a final mean of 39 U/l, for relapsed patients, P < 0.001) and ALT (from mean value of 52 U/l to 33 U/l, for abstinent patients, P < 0.001, and from 52 U/l to 38 U/l, for relapsed patients, P < 0.001) did not differ between the two groups. The ACS mean score (Table 1) in the 109 treated subjects at the start was 9.01 ± 2.64 and was 3.72 ± 2.84 at the end of the study (P < 0.001); in patients maintaining abstinence throughout the period of treatment (group A) the mean score on entrance was 9.16 ± 2.71, and at the end of the study was 3.09 ± 2.53 (P < 0.001). On the other hand, in patients who reached, but did not maintain, abstinence (group B), the mean score on starting was similar to group A (8.51 ± 2.32), but on termination of treatment it was significantly higher (5.75 ± 2.95) (P < 0.01) (Table 1). In patients, subgroup individuals who relapsed at 1 year (group D) showed starting values of craving significantly lower than patients complying with the therapy (group C) (Table 1).
4 344 G. ADDGLORATO et al. DISCUSSION The drug proved to be very manageable, giving rise to few side-effects. In particular, unwanted dizziness, sleepiness and tiredness early during treatment, due to GHB's CNS action, were foreseeable and their extent and transience supported in general the acceptability of the drug. Liver function test values in the treated subjects improved significantly and this is generally attributable to cessation of alcohol intake. The parallel reduction in indices of hepatocellular damage, however, support the general safety of the drug. On the other hand, a number of patients abused the drug, seeking its psychotropic effects. Within the limits of an open study, we observed a fair efficacy of the drug in improving the abstinence rate that is comparable with the best results obtained with other types of treatment, which vary between 24% and 60% (US Department of Health and Human Services, 1990; Bien et al., 1993). The parallel reduction in the mean ACS score of responding patients and the expected better response in patients with a higher ACS mean score add indirect support to the possibility of a link between GHB's alleged anti-craving action and its clinical efficacy. The increase in relapse in the 6 months following the end of GHB administration not only outlines the efficacy of the drug, but also draws attention to its limitations, and also favours an indirect mechanism of action of the drug. It is conceivable that GHB improves the abstinence rate, rather than influence directly alcohol dependence. Our results thus warrant a double-blind placebo-controlled study to establish the therapeutic role of GHB in alcoholism. Acknowledgements Centres participating in the GHB Study: M. Vittadini, M. Alictli: Servizio per le Alcoldipendenze, Ospedale S. Raffaele, Milano. G. Vittadini, P. Gabanelli, I. Giorgi, O. Nervi, R. Fonte: Fondazione Clinica del Lavoro, L.R.C.C.S., Universita di Pavia. M. Toti, L. Incandela: Servizio Attivita Specialistiche, U.O. Grosseto. P. Casella, D. Donati: Servizio Tossicodipendenze, Rimini. M. Scudieri: Ospedale S. Massimo, Penne. C. Groppi: Servizio Tossicodipendenze, Firenze. R. Polito, G. Zanda: Servizio Tossicodipendenze, Lucca. S. Pistoso: Ospedale Civile, Sal6. C. Vasconeuo: Servizio di Psichiatria, Siena. F. Lcder, G. Gallimberti: Nucleo Operativo Tossicodipendenze, Scregno, Milano. M. Parravicini: Centro Garbagnate, Milano. W. Liboni: Ospedale di Gradenigo, Torino. C. Baldelli, A.M. De Luca, M. Conte: U.S.L. RM/18 Ambulatorio di Alcologia, Roma. P. Casella: SERT RM/11. J. Petruzzi: IRCCS 'De Bellis'. Castellana Grotte, Ban. R. Proietti: Istituto Neurotraumatologico Italiano, Grottaferrata. G. Rastelli: I Divisione Medica SERT, Fidenza. T. Donzelli: Ospedale Vimercate, Milano. G. Belloni: Istituto di Clinica Medica I, Ospedale Civile, Pavia. M. Tonfani, A. Lucchini, F. Galanti: Nucleo Operativo Alcologia, Gorgonzola. U. Dinelli, R. Milani, G. Mottola Lucano: Park Villa Napoleon, Treviso. A. Petricca: Villa Pini d'abnizzo, Chieti. F. Cesarino: Monteripoli Medicus Hotel, Tivoli. This paper whose partially supported by 'Associazione Ricerca in Medicina'. REFERENCES Addolorato, G., Viaggi, M., Gentilini, L., Castelli, E. et al. (1993a) Alcohol addiction: evaluation of the therapeutic effectiveness of self-help group in the maintenance of abstinence from alcohol. Alcologia V, Addolorato, G., Castelli, E., Olanda, S., Stefanini, G. F. and Gasbarrini, G. (19936) Raggiungimento e mantenimento dell'astinenza da bevande alcoliche in 15 pazienti alcoldipendenti mediante trattamento ambulatoriale e farmacologico con sale sodico dell'acido 4-idrossibutirrico. Atti XI Congresso Nazionale S.I.A., Alcoholics Anonymous (1978) Twelve Steps and Twelve Traditions, 17th edn. A.A. World Services Inc., New York. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. American Psychiatric Association, Washington, DC. Bien, T. H., Miller, W. R. and Tonigan, J. S. (1993) Brief interventions for alcohol problems: a review. Addiction 88, Di Bello, M. G., Gambassi, F., Mugnai, L. et al. (1995) Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol dependent patients. Alcologia VII, Emrick, C. D. (1987) Alcoholics-Anonymous affiliation process and effectiveness as treatment. Alcoholism: Clinical and Experimental Research 11, Fuller, R. K., Brankey, L., Brightwell, D. R., Derman, R. M. et al. (1986) Disulfiram treatment of alcoholism: a veterans administration cooperative study. Journal of the American Medical Association 256, Gallimberti, L., Gentile, N., Cibin, M., Fadda, F. et al. (1989) Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet li, Gallimberti, L., Fern, M., Ferrara, S. D., Fadda, F. and Gessa, G. L. (1992) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double blind study. Alcoholism: Clinical and Experimental Research 16, Gasbarrini, G., Stefanini, G. F., Addolorato, G. and Viaggi, M. (1994) II trattamento della patologia da alcol. In L'abuso di bevande alcoliche e le principali tossicodipendenze, Wassermann, A. ed., pp Gorelick, D. A. and Paredes, A. (1992) Effect of
5 GHB TREATMENT OF ALCOHOLISM 345 fluoxetine on alcohol consumption in male alcoholics. Alcoholism: Clinical and Experimental Research 16, Hermos, J. A. (1992) Strategies for change in substance abuse: bridging community and clinical approaches. Psychology of Addictive Behavior 6, Inturri, P., Burra, P., Baldi, E., Graziotto, A. et al. (1993) Role of methadoxine in alcohol abuse. Annals of Experimental Clinical Medicine I, 1. Jacobson, N. S., Holtzworth-Munroe, A. and Schmaling, K. B. (1989) Marital therapy and spouse involvement in the treatment of depression, agoraphobia and alcoholism. Journal of Consulting and Clinical Psychology 57, Laborit, H., Jovany, J. M. and Gerard, J. (I960) Sur un substrat metabolique a action centrale inhibitrice. Le 4-Hydroxybutirate de Na. La Presse Medicate 50, Lhuintre, J. P., Moore, N., Tran, G. et al. (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and Alcoholism 25, Lieber, C. S., Casini, A., De Carli, L. M., Kim, C. I. and Lower, N. (1990) S-adenosyl-mcthionine attenuates alcohol-induced liver injury in the baboon. Hepatology 11, Mamelak, M., Scharf, M. B. and Woods, M. (1986) Treatment of narcolepsy and sleep apnea with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9, O'Farrel, T. J. (1989) Marital and family therapy in alcoholism treatment Journal of Substance Abuse Treatment 6, O'Malley, S. S., Jaffe, A., Chang, G., Witte, G. et al. (1992) Naltrexone in the treatment of alcohol dependence: Preliminary findings. In Novel Pharmacological Interventions for Alcoholism, Naranjo, C. A. and Sellers, E. M. eds, pp , Springer- Verlag, New York. Soyka, M. (1995) Multinational clinical trials on acamprosate: methodology and clinical efficacy. Alcohol and Alcoholism 31, 478. United States Department of Health and Human Services (1990) Seventh Special Report to the US Congress on Alcohol and Health, pp Vayer, P., Mandel, M. and Maitre, M. (1987) Gammahydroxybutyrate, a possible neurotransmitter. Life Sciences, 41,
BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
Alcohol & Alcoholism Vol. 37, No. 5, pp. 504 508, 2002 BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY GIOVANNI ADDOLORATO*, FABIO CAPUTO
More informationNuove frontiere nella terapia dell abuso alcolico
Le malattie da abuso da bevande alcoliche; Modena, 28 Aprile 2007 Nuove frontiere nella terapia dell abuso alcolico Giovanni Addolorato Istituto di Medicina Interna, Università Cattolica del Sacro Cuore
More informationDecreasing Alcohol Use with Medications: What Works?
Decreasing Alcohol Use with Medications: What Works? Annual Review of Family Medicine December 7 th, 2017, UCSF Mission Bay Ben Smith, MD MPH Assistant Professor of Family and Community Medicine San Francisco
More informationTreatment of alcohol addiction with high-dose Baclofen. A randomised and placebo-controlled study (BACLAD) (European Neuropsychopharmacology, 2015)
Treatment of alcohol addiction with high-dose Baclofen. A randomised and placebo-controlled study (BACLAD) (European Neuropsychopharmacology, 2015) Authors: Christian A. Müller, Olga Geisel, Patricia Pelz,
More informationNIH Public Access Author Manuscript Psychiatry Clin Neurosci. Author manuscript; available in PMC 2010 November 1.
NIH Public Access Author Manuscript Published in final edited form as: Psychiatry Clin Neurosci. 2003 October ; 57(5): 542 544. An Open Pilot Study of Gabapentin vs. Trazodone to Treat Insomnia in Alcoholic
More information4/18/2018. Disclosure Statement. Background. Learning Objectives. Background. Background
Disclosure Statement The implementation of a pharmacy run outpatient addiction clinic focusing on patients with high risk for negative outcomes with active alcohol use disorder (AUD) By Jaime Cantu April
More information2. Chapter 2: Eligibility
2.1 Overview of Approach and Goals 2. Chapter 2: Eligibility The goal is to randomize 1375 participants over 18 years of age who meet DSM-IV criteria for alcohol dependence and are abstinent for a minimum
More informationA pilot randomised controlled trial of varenicline versus oral naltrexone for the treatment of alcohol dependence. Background 1
A pilot randomised controlled trial of varenicline versus oral naltrexone for the treatment of alcohol dependence Nicholas Lintzeris, Mark Montebello, Lauren Monds, Consuelo Rivas, David Allsop, Selena
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationLong term pharmacotherapy for Alcohol Dependence: Anti Craving agents
Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationEfficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
Blackwell Science, LtdOxford, UKADDAddiction0965-2140 2004 Society for the Study of Addiction REVIEW 99 Review Article Efficacy and safety of naltrexone and acamprosate Bouza Carmen et al. Efficacy and
More information(71%) 12 (29%) [95% CI ]; 0001). (6/42 [14%]) (13/42 [31%]) 12) [SE
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study Giovanni Addolorato, Lorenzo Leggio,
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationCLINICAL INVESTIGATION OF MEDICAL PRODUCTS IN THE TREATMENT OF GENERALISED ANXIETY DISORDER, PANIC DISORDER AND OBSESSIVE- COMPULSIVE DISORDER
CLINICAL INVESTIGATION OF MEDICAL PRODUCTS IN THE TREATMENT OF GENERALISED ANXIETY DISORDER, PANIC DISORDER AND OBSESSIVE- COMPULSIVE DISORDER Guideline Title Clinical Investigation of Medical Products
More informationIf gambling treatment was evidence based, what would it look like?
If gambling treatment was evidence based, what would it look like? Professor Mark Griffiths International Gaming Research Unit Nottingham Trent University E-mail : mark.griffiths@ntu.ac.uk Website :http://ess.ntu.ac.uk/griffiths
More informationAlcohol dependence what actually works
what actually works Alcohol dependence is the most common addiction that a generalist will encounter. D Wilson, FCPsych (SA) Psychiatrist and Head of Addictions Division, University of Cape Town/Groote
More informationPharmacotherapy for Alcohol Dependence
Evidence Report/Technology Assessment: Number 3 Pharmacotherapy for Alcohol Dependence Summary Under its Evidence-Based Practice Program, the Agency for Health Care Policy and Research (AHCPR) is developing
More informationOPIOID ANTAGONISTS IN THE TREATMENT OF ALCOHOL DEPENDENCE: CLINICAL EFFICACY AND PREVENTION OF RELAPSE
Alcohol & Alcoholism, Vol. 31, Suppl. 1, pp. 77-81, 1996 OPIOID ANTAGONISTS IN THE TREATMENT OF ALCOHOL DEPENDENCE: CLINICAL EFFICACY AND PREVENTION OF RELAPSE STEPHANIE S. O'MALLEY Department of Psychiatry.
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationGroup therapy with Pathological Gamblers: results during 6, 12, 18 months of treatment
Group therapy with Pathological Gamblers: results during 6, 12, 18 months of treatment Gianni Savron, Rolando De Luca, Paolo Pitti Therapy Centre for ex-pathological gamblers and family members - Campoformido,
More informationsodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission sodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd 10 August 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationTianeptine Dependence: A Case Report
CASE REPORT Tianeptine Dependence: A Case Report Syed Nabil, Ng Chong Guan, Rusdi Abd Rashid Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract
More informationApplication of Psychotropic Drugs in Primary Care
Psychotropic Drugs Application of Psychotropic Drugs in Primary Care JMAJ 47(6): 253 258, 2004 Naoshi HORIKAWA Professor, Department of Psychiatry, Tokyo Women s Medical University Abstract: The incidence
More informationGoal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology
Goal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology The medical model and the search for underlying diseases that produce
More informationAn Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM
An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening
More informationTHE NALTREXONE CHALLENGE
THE NALTREXONE CHALLENGE DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Maureen Allen Has no conflicts of interest DONNA 68 years old Currently treated with
More informationRiunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease
Riunione Monotematica AISF 2017 Roma 5 Ottobre 2017 Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Lorenzo Leggio, M.D., Ph.D., M.Sc. Lorenzo Leggio, M.D., Ph.D., M.Sc. Il
More informationSubstance Use And Addiction Disorders, Parts 3 & 4
Substance Use And Addiction Disorders, Parts 3 & 4 1. Medication Assisted Treatment is: a. used exclusively for marijuana addiction b. the program of choice for chronic relapses c. recommended for multiple
More informationSHORT-TERM METHADONE ADMINISTRATION REDUCES ALCOHOL CONSUMPTION IN NON-ALCOHOLIC HEROIN ADDICTS
Alcohol & Alcoholism Vol. 37, No. 2, pp. 164 168, 2002 SHORT-TERM METHADONE ADMINISTRATION REDUCES ALCOHOL CONSUMPTION IN NON-ALCOHOLIC HEROIN ADDICTS F. CAPUTO*, G. ADDOLORATO 1, M. DOMENICALI, A. MOSTI
More informationINDEX. Aversion therapy (Cont.) individualized alcoholism treatment, 183 See also Electrical aversion therapy
Index Action stage bulimia and, 232 change model and, 10 movement to, 23, 51-57 self-help manuals and, 332 Addictive behaviors change model and, 3-27 cognition and, 59 See also entries under specific addictions
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Xyrem A. Prescriptions That Require Prior Authorization All prescriptions for Xyrem must be prior authorized. B. Review of Documentation
More informationBAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH
BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH THERAPEUTIC INTERVENTION AND RESOURCE MANAGEMENT: SUBSTANCE RELATED DISORDERS: CO-DEPENDENCY AND THE IMPAIRED NURSE LECTURE OBJECTIVES:
More informationDepression & Alcohol
Depression & Alcohol Black Dog Institute Mission: To advance the understanding and management of the mood disorders through Research Clinical Services Community Support Education Community Support Clinical
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationGERALD F. X. FEENEY 1 *, JASON P. CONNOR 2, ROSS MCD. YOUNG 3, JANE TUCKER 1 and ANNIE MCPHERSON 1 INTRODUCTION
Alcohol & Alcoholism Vol. 41, No. 3, pp. 321 327, 2006 Advance Access publication 8 February 2006 doi:10.1093/alcalc/agl007 COMBINED ACAMPROSATE AND NALTREXONE, WITH COGNITIVE BEHAVIOURAL THERAPY IS SUPERIOR
More informationDefinition and Diagnosis of Relapse to Drinking
Definition and Diagnosis of Relapse to Drinking T he issues of definition and diagnosis of relapse to drinking are somewhat intertwined because the methods for diagnosing relapse may differ depending on
More informationIDDT Fidelity Action Planning Guidelines
1a. Multidisciplinary Team IDDT Fidelity Action Planning Guidelines Definition: All clients targeted for IDDT receive care from a multidisciplinary team. A multi-disciplinary team consists of, in addition
More informationAlcohol And Mood Disorders. L.E. Smit, MD, FRCPC. Objectives. February 8, 2007
Alcohol And Mood Disorders L.E. Smit, MD, FRCPC February 8, 2007 1 Objectives To provide an overview of mood and anxiety disorders and alcohol use disorders. Their prevalence co-morbidity and treatment.
More informationPRIMARY CARE MEDICAL DIRECTOR v PFIZER
CASE AUTH/2378/12/10 PRIMARY CARE MEDICAL DIRECTOR v PFIZER Promotion of Champix A primary care medical director complained about the conduct of a Pfizer representative who presented at a smoking cessation
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationIntro to Concurrent Disorders
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationYour selected document
Your selected document This entry is our analysis of a study added to the Effectiveness Bank and considered particularly relevant to improving outcomes from drug or alcohol interventions in the UK. The
More informationEvaluation of Life Skills, a Model Illness Management and Recovery Program. Mona Goldman, Ph.D. and Nancy Mann, RN. Final Report.
Evaluation of Life Skills, a Model Illness Management and Recovery Program Introduction Mona Goldman, Ph.D. and Nancy Mann, RN Final Report October 25, 2006 Illness management and recovery are now recognized
More informationSetting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xyrem) Reference Number: CP.CPA.172 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationHEALTHWEST. Practice Guideline. No Prepared By: Effective: August 23, 1999 Revised: November 13, 2018
HEALTHWEST Practice Guideline No. 12-001 Prepared By: Effective: August 23, 1999 Revised: November 13, 2018 Cyndi Blair, RNBC Chief Clinical Director Approved By: Subject: Antabuse/Campral/Naltrexone Administration
More informationTechnology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325
Nalmefene for reducing alcohol consumption in people with alcohol dependence Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325 NICE 2018. All rights reserved. Subject
More information1.0 Abstract. Title. Keywords
1.0 Abstract Title Real World Evidence of the Effectiveness of Paritaprevir/r Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Austria (REAL) Keywords
More informationClinical guideline Published: 23 February 2011 nice.org.uk/guidance/cg115
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Clinical guideline Published: 23 February 2011 nice.org.uk/guidance/cg115 NICE 2018. All rights reserved.
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationTITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is
More informationWHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS
WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS René Lento, PhD Lauren Brenner, PhD September 25, 2018 DISCLOSURES None HOME BASE PROGRAM 3 LEARNING OBJECTIVES
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationRunning Head: RECOVERY ORIENTED SYSTEMS OF CARE 1. Recovery Oriented Systems of Care: How Research is Changing the Addiction Profession
Running Head: RECOVERY ORIENTED SYSTEMS OF CARE 1 Recovery Oriented Systems of Care: How Research is Changing the Addiction Profession Jacqlyn D. Stein NAADAC William L. White Student Scholarship Competition
More informationProposed Revision to Med (i)
Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and
More informationAlcohol misuse - F10 (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10)
Alcohol misuse Alcohol misuse - F10 (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10) Presenting complaints Patients may present with: depressed mood nervousness insomnia physical
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationMEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use
MEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use Louis E. Baxter, Sr., M.D., DFASAM Executive Medical Director-PAPNJ Assistant Clinical Professor Medicine Rutgers New Jersey Medical School DMHAS-Addiction
More informationThe Impaired Professional. Peter Cohen, D.O.
The Impaired Professional Peter Cohen, D.O. Definition The American Medical Association (AMA) defines impairment as the inability to practice medicine with reasonable skill and safety to patients by reason
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationColorado State Board of Medical Examiners Policy
POLICY NUMBER: 10-14 Title: Guidelines for the Use of Controlled Substances for the Treatment of Pain Date Issued: May 16, 1996 Date(s) Revised: November 18, 2004 Reference: 12-36-117, C.R.S. Purpose:
More informationPharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations
Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation
More information^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs
^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs wm, ROBERT M.JULIEN M.D.. PH.D. Claire D. Advokat, Ph.D. Louisiana State University and Joseph
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationSubstance Abuse Level of Care Criteria
Substance Abuse Level of Care Criteria Table of Contents SUBSTANCE ABUSE OUTPATIENT: Adolescent... 3 SUBSTANCE ABUSE PREVENTION: Adult... 7 OPIOID MAINTENANCE THERAPY: Adult... 8 SUBSTANCE ABUSE INTERVENTION:
More informationHealth Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
More informationThe Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014
Information for Medical & Treatment Professionals The Sinclair Method (TSM) for the Treatment of Alcoholism Clinical Research Findings and Best Protocol for Success Updated 2014 "One medication, naltrexone,
More informationCOMBINING THE AUDIT QUESTIONNAIRE AND BIOCHEMICAL MARKERS TO ASSESS ALCOHOL USE AND RISK OF ALCOHOL WITHDRAWAL IN MEDICAL INPATIENTS
Alcohol & Alcoholism Vol. 40, No. 6, pp. 515 519, 2005 Advance Access publication 15 August 2005 doi:10.1093/alcalc/agh189 COMBINING THE AUDIT QUESTIONNAIRE AND BIOCHEMICAL MARKERS TO ASSESS ALCOHOL USE
More informationD-TMS IN ALCOHOLIC PATIENTS: PRELIMINARY DATA ON STRIATAL DOPAMINE TRANSPORTER (DAT) EVALUATED BY 123 I-FP-CIT SPECT AND ON ALCOHOL CRAVING AND INTAKE
!"#$%&'(%)*+%),#-+%.('//##012234*+%5#6'7#8932'%4'/#:(+;#6'*;
More informationA study of the effect of Baclofen on blood glucose level in alcohol dependence syndrome(ads) patients at a tertiary care hospital
Original Research Article DOI: 10.18231/2393-9087.2017.0014 A study of the effect of Baclofen on blood glucose level in alcohol dependence syndrome(ads) patients at a tertiary care hospital Bharadwaj G
More informationANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY? RICHARD RIES MD PROFESSOR OF PSYCHIATRY AND DIRECTOR
More informationType of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis.
Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Record Status This is a critical abstract
More informationDr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.
David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty
More informationGamma-Hydroxybutyrate Reduces both Withdrawal Syndrome and Hypercortisolism in Severe Abstinent Alcoholics: An Open Study vs.
The American Journal of Drug and Alcohol Abuse ISSN: 0095-2990 (Print) 1097-9891 (Online) Journal homepage: http://www.tandfonline.com/loi/iada20 Gamma-Hydroxybutyrate Reduces both Withdrawal Syndrome
More informationFranchi Massimo Piergiuseppe. Policlinico Universitario G Rossi, Azienda Ospedaliera Universitaria Integrata di Verona Verona 2012
Curriculum Vitae Personal information First name(s) / Surname(s) Franchi Massimo Piergiuseppe Telephone(s) 0039 045 8122720 Fax(es) 0039 045 8123394 E-mail(s) Nationality massimo.franchi@univr.it Italian
More informationPD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease
PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease Presented By: Daniel Weintraub, M.D. Associate Professor of Psychiatry, University of Pennsylvania; Parkinson s Disease and
More informationPCSS Guidance. Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone
PCSS Guidance Topic: Original Author: Edited by: Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone Sandra A. Springer, M.D. (September 1, 2014; 1 st revision
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral
More information7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER ELEVEN CHAPTER OUTLINE. Substance Use Disorders. Oltmanns and Emery
ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are
More informationHow much lorazepam would be a lethal dose
How much lorazepam would be a lethal dose Lorazepam drug testing: How long does Lorazepam stay in the body? Lorazepam stays in the body for a short time. Lorazepam usually takes a. 23-4-2016 Benzodiazepine
More informationSubstance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationWhat I Want From Treatment User Information
What I Want From Treatment User Information The tailoring to treatment to individual needs has long been lauded, but often it is designing treatment to what the counselor thinks the client needs. This
More informationBiological Addictions Treatment. Psychology 470. Many Types of Approaches
Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationRandomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up
Addictive Behaviors 32 (2007) 3060 3064 Short communication Randomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up Michael Ussher a,, Robert West
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationThe Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 1 Expanded to include Gambling Disorder Cannabis Withdrawal and Caffeine Withdrawal are new disorders Caffeine Withdrawal
More informationPrescribing for substance misuse: alcohol detoxification. Clinical background
Prescribing for substance misuse: alcohol detoxification POMH-UK Quality Improvement Programme. Topic 14a: baseline Clinical background 1 2014 The Royal College of Psychiatrists. For further information
More informationBlending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings
William R. Miller, Ph.D. The University of New Mexico Have you noticed: that in multisite trials (like CTN) of treatments that are already evidence-based even under highly controlled, supervised, manual
More informationmhtml:file://c:\2014\articoli\x_journal FOR DRUG ADDICTION AND ALCOH...
Page 1 of 6 JOURNAL FOR DRUG ADDICTION AND ALCOHOLISM 22nd year: 1999 no 2 (abstracts and a selection of the articles in English ) Characteristics of subjects contacted by street workers of the city of
More informationThe causes of misuse:
The Drug Misuse The causes of misuse: Availability of drugs. A vulnerable personality. Adverse social environment. Regular drug taking play a role. Determining misuse and dependence, it is unclear whether
More informationHA Corporate Scholarship Program:
HA Corporate Scholarship Program: Substance Abuse Service in Psychiatry Ronnie Pao 02-10-10 The Maudsley Hospital Marina House Community Drug & Alcohol Team London Borough of Southwark Provides a Tier
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationA. Incorrect! Seizures are not typically linked to alcohol use. B. Incorrect! Epilepsy is a seizure that is commonly associated with convulsions.
Pharmacology - Problem Drill 17: Central Nervous System Depressants Question No. 1 of 10 Instructions: (1) Read the problem statement and answer choices carefully (2) Work the problems on paper as 1. occur(s)
More information